Osteoporosis, osteopenia, and inflammatory bowel disease: lessons from a real‑world study by Pellicano, Rinaldo & Ribaldone, Davide G
EDITORIAL Osteoporosis and inflammatory bowel disease 411
The availability of dual energy X ‑ray absorpti‑
ometry (DEXA) has contributed significantly to 
the increasing awareness of IBD ‑associated bone 
diseases, but considering that BMD is only a sur‑
rogate outcome, actually the WHO fracture risk 
assessment model (FRAX) is considered more ap‑
propriate to estimate a patient’s 10 ‑year proba‑
bility of developing a hip fracture or a major os‑
teoporotic fracture. Focusing on historical stud‑
ies, a survey of the Danish Crohn’s and Colitis 
Association has reported that in IBD patients 
(383 with CD and 434 with UC), the fracture risk 
was increased in the case of CD (relative risk, 
1.7) but not of UC, compared with the control 
group (n = 635).5 A population ‑based study was 
performed at the University of Manitoba, Cana‑
da, using a specific IBD database, which included 
files of all 6027 residents with IBD. Fracture risk 
was found to be approximately 1 per 100 patient‑
‑years, with an overall fracture risk of 1.41, when 
compared with 60 270 controls. Fracture risk was 
comparable between CD and UC patients, as well 
as between men and women, and increased sig‑
nificantly above the age of 60 years.6
In this issue of Polish Archives of Internal Medi-
cine (Pol Arch Intern Med), Krela ‑Kaźmierczak et al7 
evaluated, in a prospective study, the prevalence 
of osteoporosis and osteopenia in a cohort of Pol‑
ish IBD patients, as well as the influence of BMI, 
disease duration, number of hospital stays, and 
use of steroids on BMD. By using DEXA, the au‑
thors found osteoporosis of the lumbar (L2–L4) 
spine (T ‑score) in 11.7% of the patients with CD 
and in 3.8% of those with UC, whereas that of 
the femoral neck (FN), in 5.8% and 2.9% of the 
patients with CD and UC, respectively. Osteope‑
nia occurred in 35.9% (FN) to 36.9% (lumbar) 
of CD patients, and in 25.7% (FN) to 29.5% (L2–
L4) of UC patients. In CD patients, BMI was as‑
sociated with L2–L4 and FN BMD and with L2–
L4 T ‑score, whereas FN T ‑score correlated with 
BMI. Among UC patients, the cumulative dose of 
Osteoporosis is defined by the World Health Or‑
ganization (WHO) as “a systemic skeletal disease 
characterized by low bone mass and microarchi‑
tectural deterioration of bone tissue, with a con‑
sequent increase in bone fragility and susceptibil‑
ity to fracture”.1 Osteopenia is characterized by 
a decreased bone mass density (BMD), but not to 
the extent of osteoporosis.1 In healthy individu‑
als, genetics, physical activity, body mass index 
(BMI), age, diet, and ethnicity are all known de‑
terminants of osteoporosis.
The inflammatory bowel diseases (IBDs) are 
chronic inflammatory disorders of the gut. Al‑
though the pathogenesis of IBD, as well as of its 
extraintestinal manifesta tions, remains to be 
elucidated, an increasing interest is focused on 
the potential role of microbiota in the interaction 
between the immune system and environmental 
factors in genetically predisposed individuals.2
Osteoporosis has been observed in both types 
of IBD, Crohn disease (CD) and ulcerative colitis 
(UC). However, data about its prevalence in dif‑
ferent populations of IBD patients showed much 
variability due to different study designs and sam‑
ple sizes as well as to diverse geographic locations. 
A recent meta ‑analysis has shown that the glob‑
al risk of fracture, the most severe osteoporo‑
sis consequence, was increased in patients with 
IBD compared with controls (relative risk, 1.38; 
95% CI, 1.11–1.73). This increase was confined 
to vertebral fractures (odds ratio, 2.26; 95% CI, 
1.04–4.90), and did not involve other sites. Nev‑
ertheless, BMD showed a significant decrease for 
IBD patients versus controls at all sites.3 The 3 main 
pathogenetic factors involved in the association 
between IBD and osteopenia or osteoporosis are 
the impaired absorption of nutrients that are es‑
sential for the bone, such as vitamin D and calcium, 
the chronic inflammatory process affecting both 
the bowel and the bone, and the treatment with 
steroids. Age, sex, and body weight are important 
factors in the risk profile of a patient with IBD.4
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this event than those without fractures. More‑
over, steroid use was not more common among 
UC patients with fractures.11 These data suggest 
that when CD subjects are sufficiently ill to war‑
rant steroids, they are at increased risk for frac‑
tures. The greatest effects are seen in the initial 
months of treatment, especially in areas of tra‑
becular bone. Although it has been reported that 
prednisone doses as low as 2.5 mg/d increase the 
risk for fracture,12 it is unclear if this relates to the 
drug itself or to the disease for which the steroid 
was given. In fact, it has been hypothesized that 
it might be the active inflammation or other fac‑
tors related to disease severity, and not steroids 
per se, that lead to fractures. In any case, in a large 
research database covering mixed general prac‑
tice patient population, subjects who suspend‑
ed oral steroids showed a rapid decrease in frac‑
ture risk towards baseline shortly after stopping 
them.13 According to these data, a population‑
‑based study determined the BMD among pre‑
menopausal women who developed IBD before or 
after puberty. Surprisingly, the average BMD was 
no different between the 2 groups and only 4% 
had BMD in the osteoporotic range.14 It is possi‑
ble that, during the periods of disease remission 
and/or corticosteroid “holiday”, there is sufficient 
opportunity to catch up on bone deposition with 
normalization in bone mass.
In their consensus on extraintestinal manifes‑
tations of IBD, the European Crohn’s and Colitis 
Organisation reported that osteoprotective ther‑
apy is advisable in patients with low BMD and/
or additional risk factors. The latter include sys‑
temic steroid therapy. Vitamin D should be main‑
tained in the recommended range using a dose of 
~1000 IU/d or a higher dose in case of vitamin D 
deficiency. Supplemental calcium should be giv‑
en only if the dose of dietary calcium is lower 
than 800 mg/d.4 This strategy has been shown 
to be able to increase BMD in patients with IBD 
of 0.76% over 4 years.15
In conclusion, the work by Krela ‑Kaźmierczak 
et al7 offers a real ‑world picture of the actual asso‑
ciation between osteopenia or osteoporosis and 
IBD. Their findings alert clinicians to the impor‑
tance of identifying patients with low BMD, with 
the aim to treat and prevent fractures as a con‑
sequence of unidentified bone disease. Future 
studies should focus on the fracture events or 
on the FRAX score, comparing IBD patients with 
a well ‑characterized control group.
DISCLAIMER The opinions expressed by the au‑
thor are not necessarily those of the journal ed‑
itors, Polish Society of Internal Medicine, or 
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steroids correlated with L2–L4 T ‑score, FN BMD, 
T ‑score, and Z ‑score, whereas the disease dura‑
tion correlated with FN BMD, and the FN T ‑score, 
with the number of hospital stays and FN BMD. 
The authors concluded that osteopenia and osteo‑
porosis are frequent in patients with IBD, both 
in women and in men, and that BMD correlates 
with BMI in all patients and with the use of ste‑
roids (cumulative prednisone dose), as well as 
with the duration of the disease and the number 
of hospital stays in patients with UC.
Although the methodology of the study rais‑
es some critical concerns (since age and BMI are 
risk factors for osteoporosis, cases and controls 
should have been matched using the propensity 
score matching or performing a multivariate anal‑
ysis), these data give us a diagnostic and thera‑
peutic lesson.
From a diagnostic point of view, IBD patients 
should be investigated for osteopenia and osteo‑
porosis, both at baseline and during the follow‑
‑up, despite the lack of consensus in this setting. 
After the diagnosis, the aim should be to under‑
stand if the extent and duration of IBD, as well 
as the features of the patients, are associated 
with bone damage. During the follow ‑up, the aim 
should be to understand the potential influence 
of steroid treatment on BMD.
From a therapeutic standpoint, several consid‑
erations should be made. Since, clearly, it is much 
easier to prevent bone loss than to rebuild bone 
mass, the key question is if the normalization of 
vitamin D and calcium in serum influences BMD 
and reduces the risk of fractures in IBD patients.
Normal vitamin D metabolism is critical in de‑
veloping and maintaining normal BMD and, in as‑
sociation with adequate calcium levels, has been 
shown to prevent fractures in older individuals. 
In Norway, it has been reported that 27% of CD 
and 15% of UC patients had subnormal serum 
levels (<30 nmol/l) of 25 ‑hydroxyvitamin D.8 Al‑
though this suggests that supplementation with 
vitamin D is necessary in a considerable number 
of IBD patients, it should be highlighted that oth‑
er studies performed in the same context have 
shown a lack of correlation between the levels of 
serum vitamin D metabolites and BMD.9
Another question refers to the impact of ste‑
roids on the pathogenesis of bone disease. Al‑
though steroid use is a major factor in IBD‑
‑associated bone loss, it is difficult to separate 
the effects of these drugs from those of the dis‑
ease activity. Steroids have multiple mechanisms 
on bone metabolism. They impair osteoblast func‑
tion, reduce intestinal calcium absorption, while 
increasing renal calcium excretion, induce sec‑
ondary hyperparathyroidism, enhance osteoclast 
bone resorption via the production of interleukin 
1, and precipitate hypogonadism.10 This leads to 
a low bone turnover. The dose–effect relationship 
of steroid use and fracture rates has been shown 
by revisiting the Manitoba IBD cohort. CD pa‑
tients with fractures were significantly more like‑
ly to have used steroids in the 2 years prior to 
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